What are the differential diagnoses for rough follicular papules on the chest and abdomen?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Differential Diagnosis for Rough Follicular Papules on Chest and Abdomen

The differential diagnosis for rough follicular papules on the chest and abdomen includes keratosis pilaris, Malassezia (Pityrosporum) folliculitis, drug-induced papulopustular eruption (particularly from EGFR inhibitors or MEK inhibitors), bacterial folliculitis, acne vulgaris, follicular contact dermatitis, and actinic folliculitis.

Primary Considerations

Keratosis Pilaris

  • Presentation: Symmetrically distributed, monomorphic, folliculocentric hyperkeratotic papules with variable perifollicular erythema 1
  • Texture: Characteristically "spikey bumps" or rough texture
  • Distribution: Commonly affects arms, legs, and buttocks, but can involve trunk
  • Associated conditions: Often coexists with atopic dermatitis and ichthyosis vulgaris 1

Malassezia (Pityrosporum) Folliculitis

  • Presentation: Monomorphic, pruritic papules and pustules 2, 3
  • Distribution: Most commonly chest, back, posterior arms, and face 3
  • Key distinguishing feature: Pruritus is prominent and lesions are remarkably uniform in appearance
  • Clinical clue: Fails to respond to typical acne medications and may worsen with antibiotics 3
  • Diagnosis: Confirmed by KOH preparation showing yeast and spores, dermoscopy, or Wood's lamp examination 2

Drug-Induced Papulopustular Eruption

  • Medication history is critical: EGFR inhibitors (erlotinib, afatinib, cetuximab, panitumumab) or MEK inhibitors (trametinib, cobimetinib, binimetinib) 4
  • Presentation: Follicular papules and pustules initially in sebaceous-rich areas (face, forehead, nose, cheeks), progressing to chest and upper back 4
  • Timing: Develops within days to weeks after drug initiation 4
  • Incidence: 75-90% of patients on EGFR inhibitors, 74-85% on MEK inhibitors 4
  • Associated symptoms: Pruritus, stinging, and pain 4

Secondary Considerations

Bacterial Folliculitis

  • Presentation: Follicular pustules, may have surrounding erythema
  • Key features: Often painful, may have yellow crusting or discharge 5
  • Distribution: Can occur anywhere but favors areas of friction or occlusion
  • Culture: Gram stain and culture show bacterial organisms, typically Staphylococcus aureus 5

Acne Vulgaris

  • Presentation: Polymorphic lesions including comedones, papules, pustules, and possibly nodules 6
  • Distribution: Face and trunk are common sites
  • Key distinguishing feature: Presence of open and closed comedones differentiates from purely follicular conditions 6

Follicular Contact Dermatitis

  • Presentation: Individual papules with central hair follicle 7
  • History: Recent exposure to topical agents (antibiotics like neomycin, other allergens or irritants) 7
  • Pathology: Spongiosis and vesicle formation of follicular epithelium with perifollicular lymphocytic inflammation 7

Actinic Folliculitis

  • Presentation: Nonpruritic, monomorphic pustules and papules 8
  • Distribution: Face, upper chest, and arms 8
  • Timing: Appears 4-24 hours after sun exposure, resolves within 7-10 days with cessation of exposure 8
  • Seasonal pattern: Recurrent and seasonal 8

Diagnostic Approach

Step 1: Medication History

  • Review all current medications, particularly cancer therapies (EGFR inhibitors, MEK inhibitors, mTOR inhibitors)
  • Timeline of lesion onset relative to drug initiation

Step 2: Lesion Morphology Assessment

  • Monomorphic vs polymorphic: Monomorphic suggests Malassezia folliculitis, drug eruption, or keratosis pilaris; polymorphic suggests acne vulgaris
  • Texture: Rough, keratotic texture favors keratosis pilaris
  • Pustules present: Consider Malassezia folliculitis, bacterial folliculitis, or drug-induced eruption

Step 3: Associated Symptoms

  • Pruritus: Strongly suggests Malassezia folliculitis or drug-induced eruption
  • Pain: Consider bacterial folliculitis or severe drug-induced eruption
  • No symptoms: Favors keratosis pilaris

Step 4: Response to Previous Treatments

  • Failed antibiotic therapy: Strongly suggests Malassezia folliculitis 3
  • Worsened with antibiotics: Malassezia folliculitis
  • Failed typical acne medications: Consider Malassezia folliculitis or actinic folliculitis

Step 5: Diagnostic Testing When Indicated

  • KOH preparation: For suspected Malassezia folliculitis (shows yeast and spores) 2
  • Bacterial culture: If pustules are painful, have yellow crusting, or fail to respond to initial therapy 5
  • Patch testing: If contact dermatitis suspected with history of topical agent exposure 7

Critical Pitfalls to Avoid

  • Do not assume all follicular eruptions are acne: The absence of comedones should prompt consideration of other diagnoses
  • Do not prescribe antibiotics empirically for pruritic monomorphic papules: This may worsen Malassezia folliculitis 3
  • Do not overlook medication history: Drug-induced eruptions are extremely common with targeted cancer therapies and require specific management 4
  • Do not dismiss keratosis pilaris as trivial: Recognition supports diagnosis of associated atopic conditions and can reduce patient distress 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.